(News Bulletin 247) – Biophytis took off on the Paris Stock Exchange on Tuesday after unveiling a partnership with the French pharmaceutical synthesis group Seqens, which will enable the biotechnology company to secure the production of its main drug candidate.
Very volatile, the Biophytis share is currently up more than 53%, signifying by far the strongest rise in a globally stable Parisian market.
The biotech announced this morning the signing of a framework contract for the production of the active ingredient of Sarconeos (BIO101), its experimental drug developed for both severe forms of Covid-19, sarcopenia and Duchenne muscular dystrophy .
Under the terms of the agreement, Seqens will ensure the production of the molecule’s active ingredient in France, at its factory in Villeneuve La Garenne near Paris, a historical site recently modernized and extended with the opening of a unit for the production of active pharmaceutical ingredients (APIs) with high potential.
‘With this agreement, Biophytis is continuing to prepare for the potential marketing of its product in France’, react the analysts at Invest Securities in a research note.
The stockbroker recalls that the biotechnology company filed a file with HAS last month for the provision of BIO101 for hospitalized patients suffering from a severe form of Covid-19 with a risk of respiratory decompensation.
The response from HAS and ANSM is expected by the end of July according to its forecasts.
Copyright (c) 2023 News Bulletin 247. All rights reserved.
I have over 8 years of experience working in the news industry. I have worked as a reporter, editor, and now managing editor at 247 News Agency. I am responsible for the day-to-day operations of the news website and overseeing all of the content that is published. I also write a column for the website, covering mostly market news.